Side-by-side · Research reference

MazdutidevsProstamax

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED19/62 cited

BAnimal-MechanisticHUMAN-REVIEWED11/38 cited

Mazdutide

GLP-1/Glucagon Dual Agonist · Oxyntomodulin Analogue · Phase 3

9 mgWeekly doseJi 2026

12.4%Weight lossAzam 2026

Phase 3Status (China)

SQ · Abdomen · Once WeeklyJi 2026

Prostamax

Khavinson Bioregulator · Tissue-Specific Peptide

0.05 ng/mLActive concentrationZakutskiĭ 2006

2.5×SCE frequency increaseDzhokhadze 2012

4 AAPeptide length

SQ · Protocol per Khavinson tradition

01Mechanism of Action

Parameter

Mazdutide

Prostamax

Primary target

GLP-1 receptor and glucagon receptorAbdul 2026 Elmendorf 2026

Chromatin in prostatic cells — pericentromeric heterochromatin regions

Pathway

Dual agonism: GLP-1R → satiety, insulin secretion, gastric emptying delay; GCGR → hepatic lipolysis, energy expenditure, thermogenesisElmendorf 2026 Abulehia 2026

Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012

Downstream effect

Weight loss via appetite suppression (GLP-1 axis) and increased energy expenditure (glucagon axis); improved glycemic control in T2D

Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012 Zakutskiĭ 2006

Feedback intact?

Yes — physiological receptor-mediated signaling preserved

—

Origin

Synthetic oxyntomodulin analogue — endogenous peptide with dual GLP-1/glucagon activity

Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017

Antibody development

—

02Dosage Protocols

Parameter

Mazdutide

Prostamax

Phase 2 studied dose

9 mg / weekJi 2026

Highest efficacy dose in obesity trial (BMI ≥30 kg/m²).Ji 2026

—

Frequency

Once weeklyJi 2026 Luo 2026

—

Route

SubcutaneousJi 2026

—

Dose escalation

3 mg → 6 mg → 9 mg (titration schedule in trials)

Gradual escalation to minimize GI side effects.

—

Evidence basis

Phase 2 RCT / Phase 3 ongoingJi 2026 Luo 2026

Animal / organotypic cultureZakutskiĭ 2006 Dzhokhadze 2012

No randomized controlled trials in humans.

Duration (trials)

24–48 weeks

—

Population

Non-diabetic adults BMI ≥30 kg/m² or ≥27 kg/m² with comorbidities

—

Phase 3 comparator

Semaglutide 1 mg/week (DREAMS-3 trial)Luo 2026

—

Effective concentration (in vitro)

—

0.05 ng/mLZakutskiĭ 2006

Organotypic culture model; demonstrated tissue-specific stimulation.

Human clinical dose

—

Not established

No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).

Age groups studied

—

Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006 Dzhokhadze 2012

Duration

—

Not specified

Khavinson protocols typically 10–20 days per cycle; no long-term safety data.

03Metabolic / Fat Loss Evidence

Parameter

Mazdutide

Prostamax

Percentage body weight loss

12.4% (pooled meta-analysis, 9 mg dose)

95% CI: -16.15% to -8.68%, random-effects model.Azam 2026

—

Absolute weight loss

9.8 kg (mean)Azam 2026

95% CI: -13.15 to -6.37 kg.Azam 2026

—

Responder rate (≥10% loss)

Not explicitly reported in available abstracts

—

Mechanism

Appetite suppression (GLP-1) + energy expenditure (glucagon)Elmendorf 2026

—

BMI reduction

Significant reduction in Chinese adults BMI ≥30 kg/m²Ji 2026

—

Visceral fat

Expected benefit from glucagon-mediated lipolysis (not quantified in abstracts)

—

Glycemic improvement

HbA1c reduction in T2D cohort (Phase 3 DREAMS-3)

—

Comparator efficacy

Head-to-head vs semaglutide 1 mg (Phase 3 pending publication)Luo 2026

—

Key publications

Ji et al. Med 2026 · Azam et al. Diab Obes Metab 2026 · Luo et al. Contemp Clin Trials 2026

—

04Side Effects & Safety

Parameter

Mazdutide

Prostamax

Gastrointestinal symptoms

Nausea, vomiting, diarrhea (most common, GLP-1 effect)

—

Injection site reactions

Erythema, pruritus, local discomfort

—

Hypoglycemia

Low risk in non-diabetic cohort; monitor in T2D with insulin or sulfonylureas

—

Cardiovascular effects

Increased heart rate (glucagon effect, transient)

—

Pancreatitis risk

Theoretical (incretin class effect); monitor amylase/lipase if abdominal pain

—

Thyroid C-cell tumors

Black box warning for GLP-1 class (rodent data); human relevance unclear

—

Gallbladder disease

Cholelithiasis, cholecystitis (rapid weight loss effect)

—

Tolerability

Generally well-tolerated; GI effects diminish with dose titration

—

Published adverse events

—

None reported in available literature

Genotoxicity signals

—

Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications

Metal ion interactions

—

Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance

Human safety data

—

Absent — no published Phase 1/2/3 trials

Absolute Contraindications

Mazdutide

·Personal or family history of medullary thyroid carcinoma
·Multiple endocrine neoplasia syndrome type 2 (MEN 2)
·Hypersensitivity to mazdutide or excipients
·Pregnancy

Prostamax

·Active prostate malignancy — epigenetic modulation effects unknown in cancer

Relative Contraindications

Mazdutide

·History of pancreatitis
·Severe gastroparesis or GI motility disorders
·Diabetic retinopathy (monitor, risk of worsening with rapid glycemic change)
·Renal impairment (limited data, use with caution)

Prostamax

·History of prostate cancer — theoretical concern re: transcriptional activation
·Undiagnosed prostatic nodules or elevated PSA

05Administration Protocol

Parameter

Mazdutide

Prostamax

1. Preparation

Supplied as pre-filled pen or reconstituted vial (per manufacturer instructions). Inspect solution — should be clear, colorless to pale yellow. Discard if cloudy or particulate matter present.

Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.

2. Injection site

Subcutaneous — abdomen preferred, also thigh or upper arm. Rotate sites weekly. Avoid areas with scarring, moles, or active inflammation.

If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).

3. Timing

Once weekly, same day each week. May be taken with or without food. If dose missed, administer within 3 days; if >3 days, skip and resume next scheduled dose.

Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.

4. Storage

Refrigerate 2–8 °C. Do not freeze. May be kept at room temperature (<25 °C) for up to 14 days if needed. Protect from light.

No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).

5. Needle technique

Use supplied needle or compatible insulin syringe (if reconstituting). Pinch skin, inject at 90° angle. Hold 5–10 seconds before withdrawing needle to prevent leakage.

All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.